917397-93-4

Usage

Uses

Used in Pharmaceutical Industry:
2-[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propan-2-ol is used as a chemical building block for the synthesis of various pharmaceuticals. Its ability to form stable complexes with substrates and undergo Suzuki-Miyaura cross-coupling reactions makes it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
2-[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propan-2-ol is used as a chemical building block for the synthesis of various agrochemicals. Its unique structure and reactivity contribute to the development of new and effective agrochemicals.
Used in Fine Chemicals Industry:
2-[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propan-2-ol is used as a chemical building block for the synthesis of various fine chemicals. Its versatility in organic synthesis allows for the creation of a wide range of specialized chemical products.
Used in Drug Discovery:
2-[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propan-2-ol is used as a key component in drug discovery due to its potential applications in the development of new drugs. Its ability to form biaryl compounds through Suzuki-Miyaura cross-coupling reactions is particularly valuable in this field.
Used in Materials Science:
2-[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propan-2-ol is used in materials science for the development of new materials. Its unique structure and reactivity make it a promising candidate for the creation of innovative materials with various applications.

Upstream product

• 2077-19-2 2-(4-bromophenyl)propan-2-ol 
• 73183-34-3 bis(pinacol)diborane 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 99-90-1 para-bromoacetophenone 
• 106-37-6 1.4-dibromobenzene 
• 909187-36-6 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoic acid 

Relevant academic research and scientific papers

Hindered dialkyl ether synthesis with electrogenerated carbocations

Hindered ethers are of high value for various applications; however, they remain an underexplored area of chemical space because they are difficult to synthesize via conventional reactions1,2. Such motifs are highly coveted in medicinal chemistry, because extensive substitution about the ether bond prevents unwanted metabolic processes that can lead to rapid degradation in vivo. Here we report a simple route towards the synthesis of hindered ethers, in which electrochemical oxidation is used to liberate high-energy carbocations from simple carboxylic acids. These reactive carbocation intermediates, which are generated with low electrochemical potentials, capture an alcohol donor under non-acidic conditions; this enables the formation of a range of ethers (more than 80 have been prepared here) that would otherwise be difficult to access. The carbocations can also be intercepted by simple nucleophiles, leading to the formation of hindered alcohols and even alkyl fluorides. This method was evaluated for its ability to circumvent the synthetic bottlenecks encountered in the preparation of 12 chemical scaffolds, leading to higher yields of the required products, in addition to substantial reductions in the number of steps and the amount of labour required to prepare them. The use of molecular probes and the results of kinetic studies support the proposed mechanism and the role of additives under the conditions examined. The reaction manifold that we report here demonstrates the power of electrochemistry to access highly reactive intermediates under mild conditions and, in turn, the substantial improvements in efficiency that can be achieved with these otherwise-inaccessible intermediates.

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

SYK INHIBITORS

The present disclosure a Syk compound inhibitors, including state cancer and inflammation and various disease States thereof in the treatment of relates to the use of. In one aspect a particular embodiment, . given by formula I which is marked as a chemical structure of compound. In formula said, X 1, X 2, X 3, R 2, R 3, R 4, R 5, and Y has described herein is. The present disclosure of a formula I compounds or a pharmaceutically acceptable salt of pharmaceutical compositions including, mediated by Syk and to treat conditions a employing these compounds and compositions further provides a method. (by machine translation)

COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT

Compounds and compositions useful for treating disorders related to Kit are described herein.

SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN

The present invention relates to compounds of formula (I) and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN

The present invention relates to compounds of formula (I) and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223

We report here the synthesis and structure-activity relationship (SAR) of a novel series of mammalian target of rapamycin (mTOR) kinase inhibitors. A series of 4,6- or 1,7-disubstituted-3,4-dihydropyrazino[2,3-b]pyrazine-2(1H)-ones were optimized for in v

IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR

Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-KB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.

6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS

The invention provides a compound of Formula (I as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS

The invention provides a compound of Formula (I) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.